- Meeting abstract
- Open Access
Anti-keratin and anti-cyclic citrullinated peptide autoantibodies in patients with juvenile idiopathic arthritis
© BioMed Central Ltd 2002
- Received: 15 January 2002
- Published: 4 February 2002
- Juvenile Idiopathic Arthritis
- Psoriatic Arthritis
- Juvenile Idiopathic Arthritis Patient
We discuss the presence of anti-keratin antibodies (AKA) and anti-cyclic citrullinated peptide (anti-CCP) antibodies of the IgG class in sera of patients with defined juvenile idiopathic arthritis (JIA) of various subgroups with more than one year duration of the disease.
An indirect immunofluorescence test on rat oesophagus substrate (ImmuGloTM, Immco Diagnostics, Buffalo, USA) and enzyme-linked immunosorbent assay (Immunoscan RA, Eurodiagnostica, The Netherlands) were used for the detection and quantification of AKA and anti-CCP antibodies in 140 patients with JIA (64 male and 76 female) aged 2–47 years (median 16.5 years).
Overall, AKA were found in 40/140 patients (28.6%, P = 0.04) including 2/11 systemic arthritis (18.2%), 2/32 oligoarthritis (6.3%), 18/52 RF negative polyarthritis (34.6%, P = 0.01), 14/18 RF positive polyarthritis (77.8%, P = 0.000002), 2/15 enthesitis related arthritis (13.3%) and 2/3 psoriatic arthritis patients. AKA were not found in a very small cohort of patients with extended oligoarthritis (n = 4) and unclassifiable arthritis (n = 5). Only 7/122 (5.7%) patients were positive for anti-CCP. The correlation between AKA and anti-CCP was 77.1% (P = 0.05).
We conclude that while AKA antibodies measured using IIF on rat oesophagus can be detected in patients with definite JIA with more than 1 year duration of the disease, only rare occurrence of anti-CCP was observed. We conclude that AKA occurred in any JIA patient category, however when statistically compared with healthy controls significantly higher frequencies were found only in a cohort of RF positive and RF negative polyarthritis.
This research was supported by a grant of 2nd Medical Faculty, Charles University Prague, VZ No.111300003 and by 5th Framework Programme, EUROBANK, No. QLRI-2000-00010.